NEWS

Jun 08, 2020

Acepodia Provides Corporate Update and Unveils New Preclinical Allogeneic NK Cell Therapy Pipeline Candidates at BIO Digital 2020

GlobeNewswire
Apr 01, 2020

Cell-Based Immunotherapies Do Battle With Solid Tumors:

Turning NK cells into “smart” weapons

April 2020 Vol. 40 No.4 | GEN—Genetic Engineering and Biotechnology News
Jan 09, 2020

Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors

ACE1702 is a potential off-the-shelf cell therapy developed using Acepodia’s Antibody-Cell Conjugation technology
Jun 12, 2020
BioProcess Online for bioanalytics, biopurification, bioproduction
Apr 23, 2020

Better Immunotherapies Through Chemistry

The Bio Report Podcast
Acepodia Logo

Acepodia Taiwan

Rm. 7, 17F., No.99, Sec. 1, Sintai 5th Rd., Sijhih Dist., 

New Taipei City 22175, 

Taiwan (R.O.C.)

 

Acepodia USA

Burlingame, California USA

Tel:  +886-2-26976100 
info@acepodiabio.com

LinkedIn-icon.png
Twitter-icon.png

© 2020 Acepodia Inc.

All rights reserved